On Tuesday, Repligen Corporation (NASDAQ:RGEN) purchased 908 Devices Inc.’s (NASDAQ:MASS) desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. The ...
These additions are expected to complement Repligen’s downstream analytics portfolio, enabling the company to serve a broader range of modalities. According to InvestingPro data, 908 Devices has ...
(RTTNews) - Repligen Corporation (RGEN) announced the acquisition of a desktop bioprocessing analytical technology portfolio from 908 Devices for $70 million in cash. The portfolio includes four ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
However, Leerink Partners views ZipChip as a non-core asset and anticipates it may be a target for divestiture in the future. For deeper insights into Repligen’s strategic positioning and financial ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
WALTHAM, Mass., & BOSTON--(BUSINESS WIRE)--Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer ...
Repligen purchased 908 Devices’s desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results